Research programme: Rho GTP-binding protein inhibitors - ExonHit Therapeutics

Drug Profile

Research programme: Rho GTP-binding protein inhibitors - ExonHit Therapeutics

Alternative Names: EHT 0101; EHT 0206; EHT 101; EHT 1864; EHT 206

Latest Information Update: 04 Jul 2013

Price : $50

At a glance

  • Originator ExonHit Therapeutics
  • Developer Diaxonhit
  • Class Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; GTP phosphohydrolase inhibitors; Ras signal transduction pathway inhibitors; Rho GTP-binding protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease; Cancer; Chronic myeloid leukaemia

Most Recent Events

  • 19 Dec 2012 ExonHit Therapeutics has merged with InGen Biosciences to form Diaxonhit
  • 19 Nov 2009 Pharmacodynamics data from preclinical trials in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
  • 04 Sep 2008 Preclinical trials in Cancer in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top